Valuation : ACLS THER

Market Cap 886M 764M 720M 656M 1.23B 83.71B 1.24B 8.53B 3.31B 42.8B 3.33B 3.25B 141B P/E 2026 *
-9.31x
P/E 2027 * -7.65x
Enterprise Value 733M 632M 596M 543M 1.01B 69.25B 1.02B 7.05B 2.74B 35.4B 2.75B 2.69B 116B EV / Sales 2026 *
116x
EV / Sales 2027 * 139x
Free-Float
97.82%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2024-01-16
President 67 2024-11-17
Director of Finance/CFO 39 2022-12-31
Director TitleAgeSince
Chairman 56 2022-12-31
Director/Board Member 50 2014-08-31
Director/Board Member 59 2016-08-31
Change 5-day change 1-year change 3-year change Capi.($)
+1.03%-3.11%+39.80%+94.60% 68.21B
+1.62%+2.43%+48.66%+88.33% 64.25B
+3.68%+1.37%-13.22%+378.16% 26.54B
+1.91%-7.95%+2.97%-15.07% 25.61B
+1.30%+0.74%+31.66%-18.33% 19.88B
-0.38%-12.42%+224.86%+373.18% 17.13B
+0.65%-5.83%+1.44%+544.44% 14.93B
+2.94%+4.33%+57.42%+162.82% 14.1B
+1.60%+1.31%+25.18%+195.90% 12.45B
Average +1.59%-3.75%+46.53%+200.45% 29.23B
Weighted average by Cap. +1.56%-3.01%+42.54%+154.58%

Financials

2026 *2027 *
Net sales 6.34M 5.47M 5.15M 4.69M 8.77M 599M 8.84M 60.98M 23.67M 306M 23.8M 23.28M 1.01B 5.34M 4.6M 4.34M 3.95M 7.39M 504M 7.44M 51.36M 19.93M 258M 20.04M 19.61M 847M
Net income -90.33M -77.93M -73.41M -66.88M -125M -8.53B -126M -869M -337M -4.36B -339M -332M -14.33B -112M -96.91M -91.29M -83.18M -155M -10.61B -157M -1.08B -419M -5.43B -422M -413M -17.82B
Net Debt -153M -132M -124M -113M -212M -14.46B -213M -1.47B -572M -7.39B -575M -562M -24.29B -147M -126M -119M -109M -203M -13.84B -204M -1.41B -547M -7.08B -550M -538M -23.25B
Logo ACLS THER
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-